中恒集团：控股子公司莱美药业获药品注册证书

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs, which will enhance the company's product line [1] Group 1: Drug Approvals - Laimei Pharmaceutical has obtained drug registration certificates for Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, while Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1] Group 2: R&D Investment - The total R&D investment for Nicorandil tablets was approximately RMB 5.39 million, and for Ketorolac Tromethamine injection, it was around RMB 4.74 million [1] - The approval of these drugs is expected to further enrich the company's product offerings [1]